Phase II trial to topotecan in hepatocellular carcinoma: A Southwest Oncology Group study

被引：18

作者：

Wall, JG

Benedetti, JK

ORourke, MA

Natale, RB

Macdonald, JS

机构：

[1] CABARRUS MEM HOSP,CONCORD,NC

[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA

[3] OHIO STATE UNIV,CTR HLTH,COLUMBUS,OH 43210

[4] UNIV SO CALIF,SCH MED,LOS ANGELES,CA

[5] TEMPLE UNIV,PHILADELPHIA,PA 19122

来源：

INVESTIGATIONAL NEW DRUGS | 1997年 / 15卷 / 03期

关键词：

hepatocellular carcinoma; topotecan; phase II trial;

D O I：

10.1023/A:1005851804533

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hepatocellular carcinoma remains a highly chemoresistant neoplasm. In this study of the topoisomerase I inhibitor topotecan a response rate of 13.9% (95% confidence interval 4.7%-29.5%) was obtained utilizing a five consecutive day bolus infusion schedule. There were no complete responses and the median survival was only eight months. Furthermore, treatment with topotecan produced significant toxicity with two-thirds of patients experiencing life-threatening (grade 4) neutropenia. When used in this dose and schedule, topotecan does not appear to be effective for patients with advanced hepatocellular carcinoma.

引用

页码：257 / 260

页数：4

共 8 条

[1] TOPOISOMERASE-I INHIBITORS - TOPOTECAN AND IRENOTECAN [J].

CREEMERS, GJ ;

LUND, B ;

VERWEIJ, J .

CANCER TREATMENT REVIEWS, 1994, 20 (01) :73-96

[2]

JOHNSON R K, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P623

[3]

LOTZE MT, 1993, CANCER PRINCIPLES PR, P883

[4]

LUPORINI G, 1993, J SURG ONCOL S, V3, P115

[5]

RECONDO G, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P206

[6] PHASE-I AND PHARMACOLOGICAL STUDY OF TOPOTECAN - A NOVEL TOPOISOMERASE-I INHIBITOR [J].

ROWINSKY, EK ;

GROCHOW, LB ;

HENDRICKS, CB ;

ETTINGER, DS ;

FORASTIERE, AA ;

HUROWITZ, LA ;

MCGUIRE, WP ;

SARTORIUS, SE ;

LUBEJKO, BG ;

KAUFMANN, SH ;

DONEHOWER, RC .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :647-656

[7]

SIROTT MN, 1991, P AN M AM SOC CLIN, V10, P104

[8] A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE TOPOISOMERASE-I INHIBITOR TOPOTECAN (SK-AND-F-104864) GIVEN AS AN INTRAVENOUS BOLUS EVERY 21 DAYS [J].

WALL, JG ;

BURRIS, HA ;

VONHOFF, DD ;

RODRIGUEZ, G ;

KNEUPERHALL, R ;

SHAFFER, D ;

OROURKE, T ;

BROWN, T ;

WEISS, G ;

CLARK, G ;

MCVEA, S ;

BROWN, J ;

JOHNSON, R ;

FRIEDMAN, C ;

SMITH, B ;

MANN, WS ;

KUHN, J .

ANTI-CANCER DRUGS, 1992, 3 (04) :337-345

← 1 →